264 related articles for article (PubMed ID: 35668710)
1. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy.
Loap P; Orlandi E; De Marzi L; Vitolo V; Barcellini A; Iannalfi A; Dendale R; Kirova Y; Mirandola A
Acta Oncol; 2022 Aug; 61(8):979-986. PubMed ID: 35668710
[TBL] [Abstract][Full Text] [Related]
2. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY.
Baues C; Marnitz S; Engert A; Baus W; Jablonska K; Fogliata A; Vásquez-Torres A; Scorsetti M; Cozzi L
Radiat Oncol; 2018 Jul; 13(1):122. PubMed ID: 29970105
[TBL] [Abstract][Full Text] [Related]
3. Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction.
Scorsetti M; Cozzi L; Navarria P; Fogliata A; Rossi A; Franceschini D; De Rose F; Franzese C; Carlo-Stella C; Santoro A
Radiat Oncol; 2020 Jan; 15(1):12. PubMed ID: 31931861
[TBL] [Abstract][Full Text] [Related]
4. Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy.
Edvardsson A; Kügele M; Alkner S; Enmark M; Nilsson J; Kristensen I; Kjellén E; Engelholm S; Ceberg S
Acta Oncol; 2019 Jan; 58(1):95-104. PubMed ID: 30280626
[TBL] [Abstract][Full Text] [Related]
5. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer.
Celik E; Baus W; Baues C; Schröder W; Clivio A; Fogliata A; Scorsetti M; Marnitz S; Cozzi L
Radiat Oncol; 2020 May; 15(1):120. PubMed ID: 32448296
[TBL] [Abstract][Full Text] [Related]
6. Proton vs photon: A model-based approach to patient selection for reduction of cardiac toxicity in locally advanced lung cancer.
Teoh S; Fiorini F; George B; Vallis KA; Van den Heuvel F
Radiother Oncol; 2020 Nov; 152():151-162. PubMed ID: 31431365
[TBL] [Abstract][Full Text] [Related]
7. Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma.
Houlihan OA; Ntentas G; Cutter DJ; Daly P; Gillham C; McArdle O; Duane FK
Clin Transl Oncol; 2023 May; 25(5):1368-1377. PubMed ID: 36585562
[TBL] [Abstract][Full Text] [Related]
8. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation.
Cozzi L; Comito T; Loi M; Fogliata A; Franzese C; Franceschini D; Clerici E; Reggiori G; Tomatis S; Scorsetti M
Technol Cancer Res Treat; 2020; 19():1533033820980412. PubMed ID: 33287650
[TBL] [Abstract][Full Text] [Related]
9. Potential skin morbidity reduction with intensity-modulated proton therapy for breast cancer with nodal involvement.
Fellin F; Iacco M; D'Avino V; Tommasino F; Farace P; Palma G; Conson M; Giacomelli I; Zucchetti C; Falcinelli L; Amichetti M; Aristei C; Cella L
Acta Oncol; 2019 Jun; 58(6):934-942. PubMed ID: 30938217
[No Abstract] [Full Text] [Related]
10. Cardiac substructure exposure in breast radiotherapy: a comparison between intensity modulated proton therapy and volumetric modulated arc therapy.
Loap P; Tkatchenko N; Goudjil F; Ribeiro M; Baron B; Fourquet A; Kirova Y
Acta Oncol; 2021 Aug; 60(8):1038-1044. PubMed ID: 33788665
[TBL] [Abstract][Full Text] [Related]
11. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients.
de Jong BA; Battinelli C; Free J; Wagenaar D; Engwall E; Janssens G; Langendijk JA; Korevaar EW; Both S
Med Phys; 2023 Mar; 50(3):1305-1317. PubMed ID: 36373893
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
[TBL] [Abstract][Full Text] [Related]
13. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
14. Volumetric modulated arc therapy versus intensity-modulated proton therapy in the postoperative irradiation of thymoma.
Franceschini D; Cozzi L; Loi M; Franzese C; Reggiori G; Mancosu P; Clivio A; Fogliata A; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2267-2276. PubMed ID: 32514629
[TBL] [Abstract][Full Text] [Related]
15. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential.
Toltz A; Shin N; Mitrou E; Laude C; Freeman CR; Seuntjens J; Parker W; Roberge D
J Appl Clin Med Phys; 2015 Sep; 16(5):167–178. PubMed ID: 26699298
[TBL] [Abstract][Full Text] [Related]
16. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
Ntentas G; Dedeckova K; Andrlik M; Aznar MC; George B; Kubeš J; Darby SC; Cutter DJ
Pract Radiat Oncol; 2019 May; 9(3):179-187. PubMed ID: 30708133
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study.
Welsh J; Gomez D; Palmer MB; Riley BA; Mayankkumar AV; Komaki R; Dong L; Zhu XR; Likhacheva A; Liao Z; Hofstetter WL; Ajani JA; Cox JD
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1336-42. PubMed ID: 21470796
[TBL] [Abstract][Full Text] [Related]
18. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Ann Oncol; 2013 Aug; 24(8):2113-8. PubMed ID: 23619032
[TBL] [Abstract][Full Text] [Related]
19. Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer.
van der Laan HP; Anakotta RM; Korevaar EW; Dieters M; Ubbels JF; Wijsman R; Sijtsema NM; Both S; Langendijk JA; Muijs CT; Knopf AC
Acta Oncol; 2019 Dec; 58(12):1775-1782. PubMed ID: 31556764
[No Abstract] [Full Text] [Related]
20. Dose comparison of robustly optimized intensity modulated proton therapy (IMPT) vs IMRT and VMAT photon plans for testicular seminoma.
Rønde HS; Kronborg C; Høyer M; Hansen J; Bak ME; Agergaard SN; Als AB; Agerbæk M; Lauritsen J; Meidahl Petersen P; Dysager L; Kallehauge JF
Acta Oncol; 2023 Oct; 62(10):1222-1229. PubMed ID: 37683054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
